Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12594299 | 0.84 | — | — | |
| SCHEMBL4318070 | 0.83 | AXL (0.38) | — | |
| SCHEMBL14722341 | 0.82 | — | — | |
| SCHEMBL452791 | 0.82 | — | — | |
| SCHEMBL2113207 | 0.82 | — | — | |
| SCHEMBL2105174 | 0.82 | HTR2A (0.35) | — | |
| SCHEMBL10223046 | 0.79 | G6PD (0.31) | ALDH1A1RAB9A | |
| SCHEMBL14697536 | 0.78 | MELK (0.32) | KDM4ENPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL2105636 | 0.78 | PGR (0.38) | KDM4EALDH1A1KMT2A | |
| SCHEMBL1135029 | 0.78 | NR3C1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539763-B1 | AZAINDOLE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-1539763-A4 | AZAINDOLE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060058304-A1 | Azaindole kinase inhibitors | BHIDE RAJEEV S | 2006-03-16 | — | — | US | disclosed |
| US-6969717-B2 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-29 | — | — | US | disclosed |
| EP-1539763-A1 | AZAINDOLE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040063707-A1 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004009601-A1 | AZAINDOLE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063707-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | KDM4E 830/4885MEN1 2375/4885NPC1 3722/4885 |
| US-20060058304-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | KDM4E 842/4885MEN1 2526/4885NPC1 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.